On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility

Phase 1 Completed 12 enrolled Stanford University

NaSingle-groupOpen-labelPrevention

Summary

This is an exploratory prospective study investigating if addition of a COX-2 inhibitor can increase efficacy of ulipristal in disrupting ovulation at peak fertility.

Timeline

Start: 2018-03-15
Primary completion: 2019-05-31
Completion: 2019-05-31

Publications

Cahill EP, Lerma K, Shaw KA, Blumenthal PD. Potential candidate for oral pericoital contraception: evaluating ulipristal acetate plus cyclo-oxygenase-2 inhibitor for ovulation disruption. BMJ Sex Reprod Health. 2022 Jul;48(3):217-221. doi: 10.1136/bmjsrh-2021-201446. Epub 2022 Apr 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Meloxicam	Small molecule	15 mg	Oral
Subject	Ulipristal Acetate	Unknown	30 mg	Oral

Indications

No indication recorded.